Moderna, Inc. (MRNA) Down 35% YTD. Here Is Why

Moderna, Inc. (NASDAQ:MRNA) is among the 13 Best S&P 500 Stocks to Buy According to Wall Street Analysts, based on upside potential. However, 2025 has been a challenging year for the company, with a year-to-date decline of over 35% in its share price.

The biotechnology firm made a name for itself by timely developing an effective coronavirus vaccine, but has lost its team since the pandemic started to recede. Moderna, Inc. (NASDAQ:MRNA)’s financial performance has also hurt investor sentiment.

During its second-quarter earnings call on August 1, the company lowered its revenue forecast for 2025, after the deferment of UK deliveries of certain COVID vaccines to next year, overshadowing its lower-than-anticipated loss per share during the quarter.

The trimmed forecast reflected Moderna, Inc. (NASDAQ:MRNA)’s ongoing headwinds with declining demand for COVID-19 shots, slower RSV rollout, and the regulatory delays facing its new product pipeline.

While Wall Street analysts maintain a consensus Hold rating for a stock, it has an attractive one-year average share price upside potential, suggesting that a recovery could occur ahead as the company makes clinical progress on certain treatments.

While we acknowledge the potential of MRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Australian Stocks to Buy Right Now and 11 Best Large Cap Defense Stocks to Buy According to Analysts 

Disclosure: None.